These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 21044274)

  • 21. Comparison of intravitreal bevacizumab and ranibizumab treatment for diabetic macular edema.
    Ozturk BT; Kerimoglu H; Bozkurt B; Okudan S
    J Ocul Pharmacol Ther; 2011 Aug; 27(4):373-7. PubMed ID: 21631366
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term effects of therapy with ranibizumab on diabetic retinopathy severity and baseline risk factors for worsening retinopathy.
    Ip MS; Domalpally A; Sun JK; Ehrlich JS
    Ophthalmology; 2015 Feb; 122(2):367-74. PubMed ID: 25439595
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Debate on the various anti-vascular endothelial growth factor drugs.
    Khalili MR; Hosseini H
    Indian J Ophthalmol; 2008; 56(3):255-6; author reply 256. PubMed ID: 18417837
    [No Abstract]   [Full Text] [Related]  

  • 24. Antivascular endothelial growth factors in the treatment of macular oedema secondary to central retinal vein occlusion: a meta-analysis.
    Zhou S; Gao J; Xu X
    Clin Exp Ophthalmol; 2014; 42(7):637-49. PubMed ID: 24330277
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-vascular endothelial growth factor pharmacotherapy for diabetic macular edema: a report by the American Academy of Ophthalmology.
    Ho AC; Scott IU; Kim SJ; Brown GC; Brown MM; Ip MS; Recchia FM
    Ophthalmology; 2012 Oct; 119(10):2179-88. PubMed ID: 22917890
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Emerging evidence concerning systemic safety of anti-VEGF agents--should ophthalmologists be concerned?
    Lim LS; Cheung CMG; Mitchell P; Wong TY
    Am J Ophthalmol; 2011 Sep; 152(3):329-331. PubMed ID: 21855670
    [No Abstract]   [Full Text] [Related]  

  • 27. [Results of an expert survey on VEGF inhibitors in ophthalmology].
    Kühn T
    Klin Monbl Augenheilkd; 2011 Jul; 228(7):607-12. PubMed ID: 21472638
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Functional and morphological changes in diabetic macular edema over the course of anti-vascular endothelial growth factor treatment.
    Reznicek L; Cserhati S; Seidensticker F; Liegl R; Kampik A; Ulbig M; Neubauer AS; Kernt M
    Acta Ophthalmol; 2013 Nov; 91(7):e529-36. PubMed ID: 23647578
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and efficacy of intravitreal anti-VEGF injections for age-related macular degeneration.
    Jeganathan VS; Verma N
    Curr Opin Ophthalmol; 2009 May; 20(3):223-5. PubMed ID: 19367163
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR PROLIFERATIVE DIABETIC RETINOPATHY: A Systematic Review and Meta-Analysis.
    Simunovic MP; Maberley DA
    Retina; 2015 Oct; 35(10):1931-42. PubMed ID: 26398553
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Anti-VEGF inhibitors and their role in the treatment of diabetic macular oedema].
    Kakkassery V; Winterhalter S; Joussen AM
    Klin Monbl Augenheilkd; 2010 Sep; 227(9):701-11. PubMed ID: 20845250
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Avastin as an adjunct to vitrectomy in the management of severe proliferative diabetic retinopathy: a prospective case series.
    Yeoh J; Williams C; Allen P; Buttery R; Chiu D; Clark B; Essex R; McCombe M; Qureshi S; Campbell WG
    Clin Exp Ophthalmol; 2008 Jul; 36(5):449-54. PubMed ID: 18942219
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Anti-VEGF therapy to treat diabetic macular edema].
    Takamura Y
    Nippon Ganka Gakkai Zasshi; 2014 Sep; 118(9):747-9. PubMed ID: 25318182
    [No Abstract]   [Full Text] [Related]  

  • 34. Anti-VEGF therapy: comparison of current and future agents.
    Pieramici DJ; Rabena MD
    Eye (Lond); 2008 Oct; 22(10):1330-6. PubMed ID: 18497829
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparing aflibercept, bevacizumab, and ranibizumab for DME: analysis of DRCR Protocol T.
    Wykoff CC; Hariprasad SM
    Ophthalmic Surg Lasers Imaging Retina; 2015 Mar; 46(3):302-5. PubMed ID: 25835307
    [No Abstract]   [Full Text] [Related]  

  • 36. Anti-vascular endothelial growth factor pharmacotherapy for age-related macular degeneration: a report by the American Academy of Ophthalmology.
    Ip MS; Scott IU; Brown GC; Brown MM; Ho AC; Huang SS; Recchia FM;
    Ophthalmology; 2008 Oct; 115(10):1837-46. PubMed ID: 18929163
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improvement of diabetic retinopathy with intravitreal Ranibizumab.
    Kernt M; Cserhati S; Seidensticker F; Liegl R; Kampik A; Neubauer A; Ulbig MW; Reznicek L
    Diabetes Res Clin Pract; 2013 Apr; 100(1):e11-3. PubMed ID: 23391744
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bevacizumab (Avastin) for diabetic macular edema in previously vitrectomized eyes.
    Yanyali A; Aytug B; Horozoglu F; Nohutcu AF
    Am J Ophthalmol; 2007 Jul; 144(1):124-6. PubMed ID: 17601433
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative effectiveness of anti-growth factor therapies for diabetic macular edema: summary of primary findings and conclusions.
    O'Malley PG
    Arch Intern Med; 2012 Jul; 172(13):1014-5. PubMed ID: 22688778
    [No Abstract]   [Full Text] [Related]  

  • 40. Anti-VEGF for the management of diabetic macular edema.
    Stefanini FR; Badaró E; Falabella P; Koss M; Farah ME; Maia M
    J Immunol Res; 2014; 2014():632307. PubMed ID: 24741610
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.